PURPOSE: Because interleukin-10 (IL-10) seems a promising new antifibrotic drug, we investigated the pharmacokinetic and biodistribution profile of this potent therapeutic cytokine in rats with extensive liver fibrosis (BDL-3). IL-10 receptor expression was also determined in relation to these aspects. METHODS: To study the pharmacokinetic and biodistribution of IL-10, rhIL-10 was labeled with 125-iodine. Plasma samples of 125IrhIL-10 were obtained over a 30-min time period after administration of radiolabeled-cytokine to BDL-3 and normal rats. The tissue distribution was assessed 10 and 30 min after i.v. administration of 125IrhlL-10. IL-10 receptor expression was determined by immurohistochemical staining and RT-PCR technique. RESULTS: . The 125IrhIL-10 plasma curves followed two-compartment kinetics with a lower AUC in BDL-3 rats as compared to control. Plasma clearance and distribution volume at steady state were larger in BDL-3 rats. Tissue distribution analysis in normal rats showed that 125IrhIL-10 highly accumulated in kidneys. In BDL-3 rats, the liver content of 125IrhIL-10 increased by a factor of 2, whereas kidney accumulation did not significantly change. Immunohistochemical staining and RT-PCR analysis showed that IL-10 receptor was clearly upregulated in BDL-3 rat livers. CONCLUSIONS: . In normal rats, 125IrhIL-10 rapidly disappears from the circulation, and the kidney is predominantly responsible for this. In BDL-3 rats, the liver largely contributes to this rapid plasma disappearance, probably due to an increase in IL-10 receptor expression. The extensive renal clearance of IL-10 in vivo may limit a clinical application of this cytokine for the treatment of chronic liver diseases. To optimize the therapeutic effects of IL-10 in hepatic diseases, alternative approaches that either decrease renal disposition or that further enhance hepatic delivery should be considered.
PURPOSE: Because interleukin-10 (IL-10) seems a promising new antifibrotic drug, we investigated the pharmacokinetic and biodistribution profile of this potent therapeutic cytokine in rats with extensive liver fibrosis (BDL-3). IL-10 receptor expression was also determined in relation to these aspects. METHODS: To study the pharmacokinetic and biodistribution of IL-10, rhIL-10 was labeled with 125-iodine. Plasma samples of 125IrhIL-10 were obtained over a 30-min time period after administration of radiolabeled-cytokine to BDL-3 and normal rats. The tissue distribution was assessed 10 and 30 min after i.v. administration of 125IrhlL-10. IL-10 receptor expression was determined by immurohistochemical staining and RT-PCR technique. RESULTS: . The 125IrhIL-10 plasma curves followed two-compartment kinetics with a lower AUC in BDL-3 rats as compared to control. Plasma clearance and distribution volume at steady state were larger in BDL-3 rats. Tissue distribution analysis in normal rats showed that 125IrhIL-10 highly accumulated in kidneys. In BDL-3 rats, the liver content of 125IrhIL-10 increased by a factor of 2, whereas kidney accumulation did not significantly change. Immunohistochemical staining and RT-PCR analysis showed that IL-10 receptor was clearly upregulated in BDL-3 rat livers. CONCLUSIONS: . In normal rats, 125IrhIL-10 rapidly disappears from the circulation, and the kidney is predominantly responsible for this. In BDL-3 rats, the liver largely contributes to this rapid plasma disappearance, probably due to an increase in IL-10 receptor expression. The extensive renal clearance of IL-10 in vivo may limit a clinical application of this cytokine for the treatment of chronic liver diseases. To optimize the therapeutic effects of IL-10 in hepatic diseases, alternative approaches that either decrease renal disposition or that further enhance hepatic delivery should be considered.
Authors: David R Nelson; Zhengkun Tu; Consuelo Soldevila-Pico; Manal Abdelmalek; Haizhen Zhu; Yi Ling Xu; Roniel Cabrera; Chen Liu; Gary L Davis Journal: Hepatology Date: 2003-10 Impact factor: 17.425
Authors: L Beljaars; G Molema; B Weert; H Bonnema; P Olinga; G M Groothuis; D K Meijer; K Poelstra Journal: Hepatology Date: 1999-05 Impact factor: 17.425
Authors: Ana Andres-Hernando; Belda Dursun; Christopher Altmann; Nilesh Ahuja; Zhibin He; Rhea Bhargava; Charles E Edelstein; Alkesh Jani; Thomas S Hoke; Christina Klein; Sarah Faubel Journal: Nephrol Dial Transplant Date: 2012-07-09 Impact factor: 5.992
Authors: Paula Dennen; Christopher Altmann; Jonathan Kaufman; Christina L Klein; Ana Andres-Hernando; Nilesh H Ahuja; Charles L Edelstein; Melissa A Cadnapaphornchai; Angela Keniston; Sarah Faubel Journal: Crit Care Date: 2010-10-13 Impact factor: 9.097
Authors: Kathleen D Liu; Christopher Altmann; Gerard Smits; Catherine D Krawczeski; Charles L Edelstein; Prasad Devarajan; Sarah Faubel Journal: Crit Care Date: 2009-07-01 Impact factor: 9.097